Research programme: phosphodiesterase 10A inhibitors - Pfizer

Drug Profile

Research programme: phosphodiesterase 10A inhibitors - Pfizer

Alternative Names: PF-03188212; PQ-10; TP-10

Latest Information Update: 08 Feb 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Phosphodiesterase 10A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Psychotic disorders

Most Recent Events

  • 21 Oct 2009 Preclinical development is ongoing in USA
  • 19 Nov 2008 Preclinical pharmacodynamics data presented at the 38th Annual Meeting of the Society for Neuroscience (SfN-2008)
  • 31 Oct 2006 Preclinical trials in Psychotic disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top